Table 2.

Effect of rhIGF1 therapy on height SDS in the treatment-naïve/prepubertal (NPP) subgroups with or without LS (registry population). Mean (s.d./95% CI) are not reported if the n is < 5. Responders were defined as patients with a change in height SDS in year 1 of ≥ 0.3. Poor-responders were defined as patients with a change in height SDS in year 1 of < 0.3.

	NPP-LS (n = 21)				NPP-non-LS (n = 114)				P valuea	NPP-non-LS-responders (n = 50)				NPP-non-LS-poor-responders (n = 38)				P valueb
			Change from baseline				Change from baseline					Change from baseline				Change from baseline
	n	Mean (s.d.)	n	Mean (95% CI)	n	Mean (s.d.)	n	Mean (95% CI)		n	Mean (s.d.)	n	Mean (95% CI)	n	Mean (s.d.)	n	Mean (95% CI)
1 year	15	–4.68 (1.83)	10	0.70 (0.29; 1.10)	95	–3.07 (1.05)	88	0.37 (0.28; 0.45)	0.019	50	–2.85 (1.11)	50	0.64 (0.57; 0.71)	38	–3.44 (0.96)	38	0.01 (–0.06; 0.08)	<0.001
2 years	14	–4.26 (1.85)	10	1.23 (0.57; 1.88)	81	–2.83 (1.09)	77	0.64 (0.51; 0.77)	0.044	40	–2.54 (1.07)	40	0.91 (0.77; 1.05)	29	–3.28 (1.10)	29	0.20 (0.06; 0.34)	<0.001
3 years	11	–3.85 (2.11)	9	1.20 (0.36; 2.03)	67	–2.51 (1.15)	62	0.88 (0.73; 1.02)	0.173	33	–2.25 (1.06)	33	1.15 (0.98; 1.32)	23	–2.87 (1.33)	23	0.55 (0.31; 0.78)	<0.001
4 years	10	–3.83 (2.14)	8	1.33 (0.33; 2.33)	49	–2.25 (1.08)	46	1.03 (0.89; 1.17)	0.211	25	–2.15 (1.11)	25	1.21 (1.03; 1.40)	13	–2.52 (0.90)	13	0.76 (0.54; 0.99)	0.004
5 years	10	–3.99 (2.34)	8	1.12 (0.08; 2.15)	32	–1.93 (1.03)	28	1.11 (0.92; 1.30)	0.983	20	–1.92 (0.96)	20	1.25 (1.06; 1.45)	5	–2.33 (0.26)	5	0.73 (0.15; 1.31)	0.045

^aNPP-non-LS vs NPP-LS mean height SDS. ^bNPP-non-LSe-responders vs NPP-non-LS-poor-responders mean height SDS.

n, number of patients with available data at each time point. LS, Laron syndrome; SDS, standard deviation score.